Tradestie Institutional Equity Comparison Engine

AKRO vs KURA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKRO Overall Edge

AKRO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical while KURA counters with relative strength in Options & Structure. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus KURA at N/M Forward P/E and -394.3% operating margin (+10.1% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against KURA sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AKRO N/M vs KURA N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin 0.0% vs -394.3% ยท YoY +0.0% vs +10.1%
Momentum & Technical Winner AKRO
1Y +76.8% vs -39.0% ยท 52W Pos 90% vs 2%
Options & Structure Winner KURA
UNCLASSIFIED (30th %ile IV) vs BREAKDOWN (20th %ile IV)
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$6.91
-5.99% 1D
Market Cap $675.3M
1M Return -29.92%
1Y Return -38.96%
Forward P/E N/M
Unified AI Score
72.4 / 100 BUY
Tech 81.0 Fund 75.0 Flow 67.0 Mom 74.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKRO +76.75% KURA -38.96% Spread: +2.26 pp (KURA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKRO TTM Op. Margin: 0.0% KURA TTM Op. Margin: -394.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs KURA. Trailing 12-month operating profitability (AKRO 0.0% vs KURA -394.3%) and valuation multiples (AKRO N/M vs KURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKRO (5) vs KURA (2)
Institutional Metric AKRO KURA Criterion Row Winner
Market Capitalization Scale $4.5B $675.3M Larger Scale AKRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +10.1% Higher Growth KURA
Operating Margin (TTM) Profitability 0.0% -394.3% Higher Margin AKRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -34.5% -224.8% Higher ROE AKRO
52-Week Range Position Momentum 90% ($21โ€“$58) 2% ($7โ€“$14) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.90ฮฒ ยท 2% Vol 1.37ฮฒ ยท 107% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 60.0 / 100 (BUY) 72.4 / 100 (BUY) Higher Composite KURA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKRO vs KURA Buy Guide
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KURA BREAKDOWN
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live KURA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKRO nor KURA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.